TARCEVA: A randomised, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.
A randomised, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer to improve progression-free survival.
European Organisation for Research and Treatment of Cancer
830 participants
Oct 15, 2005
Interventional
Conditions
Summary
To determine whether the administration of Erlotinib (maintenance treatment) after first line chemotherapy in patients with ovarian cancer can provide improved outcomes in terms of progression-free survival, compared with the standard approach of observation alone. Roche only will be supplying the drug.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1)Treatment Arm: Erlotinib 150 mg orally, administered on a daily basis, up to 2 years
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12607000071426